HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baalasubramanian, S. Articles by Morgan, B. P. Search for Related Content PubMed PubMed Citation Articles by Baalasubramanian, S. Articles by Morgan, B. P.

CD59a Is the Primary Regulator of Membrane Attack Complex Assembly in the Mouse¹

Sivasankar Baalasubramanian^*, Claire L. Harris^*, Rossen M. Donev^*, Masashi Mizuno^*, Nader Omidvar^*, Wen-Chao Song and B. Paul Morgan^2,*

^* Complement Biology Group, Department of Medical Biochemistry and Immunology, University of Wales College of Medicine, Cardiff, United Kingdom; and Center for Experimental Therapeutics and Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104

Gene-deleted mice have provided a potent tool in efforts to understand the roles of complement and complement-regulating proteins in vivo. In particular, mice deficient in the membrane regulators complement receptor 1-related gene/protein y, decay-accelerating factor, or CD59 have demonstrated homeostatic relevance and backcrossing between the strains has revealed cooperativity in regulation. In mouse, genes encoding decay-accelerating factor and CD59 have been duplicated and show differential expression in tissues, complicating interpretation and extrapolation of findings to man. The first described form of CD59, CD59a, is broadly distributed and deletion of the cd59a gene causes a mild hemolytic phenotype with increased susceptibility in complement-mediated disease models. The distribution of the second form, CD59b, was originally described as testis specific, but later by some as widespread. Deletion of the cd59b gene caused a severe hemolytic and thrombotic phenotype. To apply data from these mouse models to man it is essential to know the relative distribution and functional roles of these two forms of CD59. We have generated new specific reagents and used them in sensitive quantitative analyses to comprehensively characterize expression of mRNA and protein and functional roles of CD59a and CD59b in wild-type (wt) and CD59a-negative mice. cd59b mRNA was detected only in testis and, at very low levels, in bone marrow. CD59b protein was present on mature spermatozoa and precursors and, in trace amounts, erythrocytes. Erythrocyte CD59b did not inhibit complement lysis except when CD59a was absent or blocked. These data confirm that CD59a is the primary regulator of complement membrane attack in mouse.

This article has been cited by other articles:

				B. Sivasankar, M. P. Longhi, K. M. E. Gallagher, G. J. Betts, B. P. Morgan, A. J. Godkin, and A. M. Gallimore CD59 Blockade Enhances Antigen-Specific CD4+ T Cell Responses in Humans: A New Target for Cancer Immunotherapy? J. Immunol., May 1, 2009; 182(9): 5203 - 5207. [Abstract] [Full Text] [PDF]

				G. Wu, W. Hu, A. Shahsafaei, W. Song, M. Dobarro, G. K. Sukhova, R. R. Bronson, G.-p. Shi, R. P. Rother, J. A. Halperin, et al. Complement Regulator CD59 Protects Against Atherosclerosis by Restricting the Formation of Complement Membrane Attack Complex Circ. Res., February 27, 2009; 104(4): 550 - 558. [Abstract] [Full Text] [PDF]

				D. D. Kim, T. Miwa, Y. Kimura, R. A. Schwendener, M. van Lookeren Campagne, and W.-C. Song Deficiency of decay-accelerating factor and complement receptor 1-related gene/protein y on murine platelets leads to complement-dependent clearance by the macrophage phagocytic receptor CRIg Blood, August 15, 2008; 112(4): 1109 - 1119. [Abstract] [Full Text] [PDF]

				R. M. Donev, L. C. Gray, B. Sivasankar, T. R. Hughes, C. W. van den Berg, and B. P. Morgan Modulation of CD59 Expression by Restrictive Silencer Factor-Derived Peptides in Cancer Immunotherapy for Neuroblastoma Cancer Res., July 15, 2008; 68(14): 5979 - 5987. [Abstract] [Full Text] [PDF]

				N. S. Bora, S. Kaliappan, P. Jha, Q. Xu, B. Sivasankar, C. L. Harris, B. P. Morgan, and P. S. Bora CD59, a Complement Regulatory Protein, Controls Choroidal Neovascularization in a Mouse Model of Wet-Type Age-Related Macular Degeneration J. Immunol., February 1, 2007; 178(3): 1783 - 1790. [Abstract] [Full Text] [PDF]

				M. P. Longhi, B. Sivasankar, N. Omidvar, B. P. Morgan, and A. Gallimore Cutting Edge: Murine CD59a Modulates Antiviral CD4+ T Cell Activity in a Complement-Independent Manner J. Immunol., December 1, 2005; 175(11): 7098 - 7102. [Abstract] [Full Text] [PDF]